- Home
- MLYS vs FRPT Comparison
MLYS vs FRPT Comparison
Compare MLYS & FRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- FRPT
- Stock Information
- Founded
- MLYS 2019
- FRPT 2004
- Country
- MLYS United States
- FRPT United States
- Employees
- MLYS N/A
- FRPT N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- FRPT Packaged Foods
- Sector
- MLYS Health Care
- FRPT Consumer Staples
- Exchange
- MLYS Nasdaq
- FRPT Nasdaq
- Market Cap
- MLYS 3.1B
- FRPT 3.1B
- IPO Year
- MLYS 2023
- FRPT 2014
- Fundamental
- Price
- MLYS $38.06
- FRPT $53.50
- Analyst Decision
- MLYS Strong Buy
- FRPT Buy
- Analyst Count
- MLYS 6
- FRPT 16
- Target Price
- MLYS $42.60
- FRPT $117.27
- AVG Volume (30 Days)
- MLYS 1.6M
- FRPT 1.6M
- Earning Date
- MLYS 11-10-2025
- FRPT 11-03-2025
- Dividend Yield
- MLYS N/A
- FRPT N/A
- EPS Growth
- MLYS N/A
- FRPT 28.97
- EPS
- MLYS N/A
- FRPT 0.66
- Revenue
- MLYS N/A
- FRPT $1,044,013,000.00
- Revenue This Year
- MLYS N/A
- FRPT $16.18
- Revenue Next Year
- MLYS N/A
- FRPT $12.89
- P/E Ratio
- MLYS N/A
- FRPT $81.06
- Revenue Growth
- MLYS N/A
- FRPT 19.30
- 52 Week Low
- MLYS $8.24
- FRPT $48.41
- 52 Week High
- MLYS $41.09
- FRPT $164.07
- Technical
- Relative Strength Index (RSI)
- MLYS 62.11
- FRPT 47.32
- Support Level
- MLYS $37.32
- FRPT $52.29
- Resistance Level
- MLYS $40.51
- FRPT $56.01
- Average True Range (ATR)
- MLYS 2.09
- FRPT 2.00
- MACD
- MLYS -0.77
- FRPT 0.74
- Stochastic Oscillator
- MLYS 43.86
- FRPT 66.97
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.